The Mycobacterium Vaccae is a exclusive product of Zhifei Longcom. Zhifei Longcom obtained the Drug Registration Approval issued by the State Food and Drug Administration on Jan.23, 2001(No.: 2001SB002, Drug Approval No.: Guoyao Zhunzi S20010003). Zhifei Longcom obtained the New Drug Certificate issued by the SFDA on Jan. 12,1999 (certificate number: Guoyao Zhengzi（1999）S-03), The product was on market officially in XXX,XXX.
The feature: A new bi-directional immunomodulatory agents; Stable and reliable quality ; Low rate of adverse reaction; Vaccae is the only immune preparation WHO in tuberculosis research and development "strategic" recommended for tuberculosis.
